65,437 trials
Neurofibromatosis Type 1 · Recurrent Childhood Pilocytic Astrocytoma · Recurrent Childhood Visual Pathway Glioma
Primary: Number of Patients Who Demonstrate Complete or Partial Response — 4; 4 Participants
Transient Ischemic Attack · Stroke · Atrial Fibrillation
Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants
Hyperemesis Gravidarum · Pregnancy Related
Primary: Blood Cholecystokinin (CCK) Levels — 53.13; 54.55; 73.61; 81.24 picogram/mililiters (pg/ml) — p=0.05
Refractory Hypertension
Primary: Change Ambulatory Systolic Blood Pressure — -29.3 mmHg
Fabry Disease
Primary: Number Of Participants Who Experienced Treatment-related Treatment-emergent Adverse Events (TEAEs) — 5 Participants
HIV Infections · Tuberculosis
Primary: LNG Area Under the Concentration-time Curve (AUC0-8h) Calculated Based on Intensive LNG PK Samples Obtained From Individual Participants — 52.13; 102.13; 80.50; 124.39…
Cocaine Use Disorder · Contingency Management
Primary: Longest Duration of Abstinence From Cocaine — 4.14; 6.64; 6.93 weeks — p=.01
Isolated Clubfoot
Primary: Kaplan-Meier Recurrence-Free Survival Probability for Clubfoot Affected Limbs — 0.81; 0.65 survival probability — p=0.03
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Weight · Food Choice · Nutrition Intake
Primary: Weight Change — 0.6; 0.4 kg — p=0.70
Influenza
Primary: Mean Change of HAI Serum Antibody Titers to A/California/07/09 (H1N1) — 1937; 383; 607 titer
Hemophilia A
Primary: ITI Success — 1; 2; 6; 7 Participants
Depression
Primary: Change in HAM-D Score From Baseline to Week 1 — -7.6 score on a scale
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Primary: Phase 1: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0 percentage of participants
Non-HPV Locally Advanced Head and Neck Cancer
Primary: Percentage of Participants Alive Without Progression (Progression-free Survival) — 34.6; 43.1 percentage of participants — p=0.3436